Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: Therapeutic implications

被引:27
|
作者
Michiels, Jan J.
Berneman, Zwi
Gadisseur, Alain
van der Planken, Marc
Schroyens, Wilfried
Budde, Ulrich
van Viiet, Huub H. D. M.
机构
[1] Univ Antwerp Hosp, Dept Hematol, Antwerp, Belgium
[2] Univ Antwerp Hosp, Dept Biol Clin, Lab Hemostasis & Hematol, Antwerp, Belgium
[3] Coagulat Lab, Hamburg, Germany
[4] Erasmus MC, Rotterdam, Netherlands
[5] Hemostasis Thrombosis & Vasc Res Ctr, Goodheart Inst, Rotterdam, Netherlands
来源
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2006年 / 32卷 / 06期
关键词
acquired von Willebrand syndrome (AvWS); systemic lupus erythematosus; monoclonal gammopathy; hypothyroidism; Wilms' tumor; thrombocythemia; diagnosis; treatment;
D O I
10.1055/s-2006-949663
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The most common nonimmune etiology of acquired von Willebrand syndrome (AvWS) includes hypothyroldism, Wilms' tumor, thrombocythemia, or congenital heart defects, and the use of various drugs. AvWS type 1 in patients with hypothyroidism is due to decreased Willebrand factor (vWF) synthesis and is reversible by treatment with thyroxin. AvWS type 1 or 3 in children with Wilms' tumor disappears after successful chemotherapy or tumor resection but the mechanism of the vWF deficiency is unknown. The AvWS type 2 in patients with thrombocythemia of various myeloproliferative disorders is caused by increased proteolysis of large vWF multimers at increasing platelet counts to above 1000 x 10(9)/L. Reduction of platelet counts to normal results in correction of the vWF parameters together with disappearance of the bleeding tendency. Type 2-like AvWS in children with congenital heart valve defects is caused by shear stress-induced proteolysis of large vWF multimers and is reversible after surgical correction. AvWS associated with the use of drugs disappears after discontinuation of the causative agent. Immune-mediated AvWS is associated with either systemic lupus erythernatosus (SLE) or immunoglobulin G (IgG) benign monoclonal gammopathy (BMG), and usually shows a type 2 vWF deficiency. Using a simple enzyme-linked immunosorbent assay, an IgG antibody against vWF is detectable in AvWS associated with SLE and IgG BMG. The IgG-autoantibodrfactor (F) vWF/VIII complex is rapidly cleared from the circulation, which explains the combined FVIII:coagulant activity (C) and vWF deficiency and the poor responses of FVIII:C and vWF parameters to intravenous desmopressin acetate and vWF/FVIII concentrates. A transient correction of both FVIII:C and vWF parameters to normal for a few weeks after high-dose intravenous immunoglobulin is seen in AvWS associated with SLE and IgG BMG. AvWS associated with SLE uniformly shows a curative response to corticosteroids. AvWS associated with IgG BMG does not respond to corticosteroids, immune suppression, or chemotherapy. AvWS associated with IgM BMG is rare and does not respond to any conventional treatment.
引用
收藏
页码:577 / 588
页数:12
相关论文
共 50 条
  • [21] Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy
    Lavin, M.
    Brophy, T. M.
    Rawley, O.
    O'Sullivan, J. M.
    Hayden, P. J.
    Browne, P. V.
    Ryan, K.
    O'Connell, N.
    O'Donnell, J. S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (06) : 1200 - 1205
  • [22] Daratumumab as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy
    Mathew Thomas, Vinay
    Gilreath, Jeffrey A.
    Newton, Shawn
    Smock, Kristi J.
    Lim, Ming Y.
    HAEMOPHILIA, 2021, 27 (04) : E563 - E566
  • [23] Von Willebrand factor antigen in systemic lupus erythematosus and antiphospholipid syndrome
    Novikov, AA
    Alexandrova, EN
    Popkova, TV
    Reshetnyak, TM
    Novikova, DS
    Baranov, AA
    Nasonov, EL
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 251 - 251
  • [24] Acquired von Willebrand syndrome in a patient with monoclonal gammopathy of unknown significance: A case report
    Gupta, Garima
    Veedu, Janeesh Sekkath
    Chahine, Zena
    Iragavarapu, Chaitanya
    CLINICAL CASE REPORTS, 2024, 12 (02):
  • [25] ACQUIRED VON WILLEBRANDS SYNDROME AND SYSTEMIC LUPUS-ERYTHEMATOSUS
    JONES, NF
    PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON, 1972, 65 (06): : 561 - &
  • [26] Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: Comparison of three different therapeutic approaches
    Federici, AB
    Stabile, F
    Castaman, G
    Canciani, MT
    Mannucci, PM
    BLOOD, 1998, 92 (08) : 2707 - 2711
  • [27] Acquired von Willebrand disease in a patient with angiodysplasia resulting from immune-mediated clearance of von Willebrand factor
    Inbal, A
    Bank, I
    Zivelin, A
    Varon, D
    Dardik, R
    Shapiro, R
    Rosenthal, E
    Shenkman, B
    Gitel, S
    Seligsohn, U
    BRITISH JOURNAL OF HAEMATOLOGY, 1997, 96 (01) : 179 - 182
  • [28] Successful treatment of acquired von Willebrand syndrome associated with monoclonal gammopathy Breaking a dangerous bond
    Jeryczynski, Georg
    Agis, Hermine
    Eichinger-Hasenauer, Sabine
    Krauth, Maria Theresa
    WIENER KLINISCHE WOCHENSCHRIFT, 2022, 134 (11-12) : 478 - 482
  • [29] ACQUIRED VON WILLEBRAND SYNDROME IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: A FOCUS ON RESPONSE TO TREATMENT WITH IVIG
    Tan, Tanna
    Pruthi, Rajiv K. K.
    Ashrani, Aneel A.
    Sridharan, Meera
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 124 - 125
  • [30] Von Willebrand factor levels in patients with systemic lupus erythematosus and antiphospholipid syndrome
    Toth, N. K.
    Tarr, T.
    Soltesz, P.
    Sarkady, F.
    Kappelmayer, J.
    Muszbek, L.
    Bagoly, Z.
    CLINICA CHIMICA ACTA, 2022, 530 : S176 - S176